ATE552239T1 - 2-methylen-20-methyl-19,24,25,26,27-pentanor- vitamin-d-analoga - Google Patents

2-methylen-20-methyl-19,24,25,26,27-pentanor- vitamin-d-analoga

Info

Publication number: ATE552239T1
Authority: AT; Austria
Prior art keywords: vitamin; methylene; methyl; skin; compound
Prior art date: 2007-12-28

Application number

AT08867299T

Other languages

English (en)

Inventor

Hector Deluca

Margaret Clagett-Dame

Lori Plum

Agnieszka Glebocka

Rafal Sicinski

Original Assignee

Wisconsin Alumni Res Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-28

Filing date

2008-12-24

Publication date

2012-04-15

2008-12-24 Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found

2012-04-15 Application granted granted Critical

2012-04-15 Publication of ATE552239T1 publication Critical patent/ATE552239T1/de

Links

229940088594 vitamin Drugs 0.000 title 1
229930003231 vitamin Natural products 0.000 title 1
235000013343 vitamin Nutrition 0.000 title 1
239000011782 vitamin Substances 0.000 title 1
150000003722 vitamin derivatives Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
208000023275 Autoimmune disease Diseases 0.000 abstract 1
208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 abstract 1
206010013786 Dry skin Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
208000037979 autoimmune inflammatory disease Diseases 0.000 abstract 1
230000000125 calcaemic effect Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
230000004069 differentiation Effects 0.000 abstract 1
230000037336 dry skin Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
210000001616 monocyte Anatomy 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1
201000006409 renal osteodystrophy Diseases 0.000 abstract 1
210000002374 sebum Anatomy 0.000 abstract 1
230000028327 secretion Effects 0.000 abstract 1
208000017520 skin disease Diseases 0.000 abstract 1
239000011710 vitamin D Substances 0.000 abstract 1
239000011647 vitamin D3 Substances 0.000 abstract 1
229940046008 vitamin d Drugs 0.000 abstract 1
229940021056 vitamin d3 Drugs 0.000 abstract 1
230000037303 wrinkles Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Immunology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Neurology (AREA)
Transplantation (AREA)
Neurosurgery (AREA)
Child & Adolescent Psychology (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT08867299T 2007-12-28 2008-12-24 2-methylen-20-methyl-19,24,25,26,27-pentanor- vitamin-d-analoga ATE552239T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US1723307P	2007-12-28	2007-12-28
PCT/US2008/088276 WO2009086440A1 (en)	2007-12-28	2008-12-24	2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin d analogs

Publications (1)

Publication Number	Publication Date
ATE552239T1 true ATE552239T1 (de)	2012-04-15

Family

ID=40616778

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT08867299T ATE552239T1 (de)	2007-12-28	2008-12-24	2-methylen-20-methyl-19,24,25,26,27-pentanor- vitamin-d-analoga

Country Status (9)

Country	Link
US (1)	US7943601B2 (de)
EP (1)	EP2240438B1 (de)
JP (1)	JP2011507966A (de)
AT (1)	ATE552239T1 (de)
AU (1)	AU2008345086B2 (de)
CA (1)	CA2710977C (de)
ES (1)	ES2387714T3 (de)
MX (1)	MX2010007205A (de)
WO (1)	WO2009086440A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2475367A1 (de) *	2009-09-10	2012-07-18	Centre National De La Recherche Scientifique	Neuartige stearoyl-coa-desaturase-1-hemmer und ihre verwendung
US8519169B2 (en)	2011-08-30	2013-08-27	Wisconsin Alumni Research Foundation	Crystallization a 1alpha-hydroxy-20-methyl-2-methylene-19,24,25,26,27-pentanorvitamin D3
RU2477635C1 (ru) *	2012-02-14	2013-03-20	Глеб Иванович Кирьянов	Способ получения инцистерола
CN110099898B (zh)	2016-10-24	2023-07-25	优曼尼蒂治疗公司	化合物及其用途
CA3049010A1 (en)	2017-01-06	2018-07-12	Yumanity Therapeutics, Inc.	Methods for the treatment of neurological disorders
CA3083000A1 (en)	2017-10-24	2019-05-02	Yumanity Therapeutics, Inc.	Compounds and uses thereof
BR112020019191A2 (pt)	2018-03-23	2021-01-05	Yumanity Therapeutics, Inc.	Compostos e seus usos
KR20220007845A (ko)	2019-01-24	2022-01-19	유마니티 테라퓨틱스, 인크.	화합물 및 이의 용도
EA202192047A1 (ru)	2019-11-13	2021-12-08	Юманити Терапьютикс, Инк.	Соединения и их применение

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4666634A (en) *	1984-12-05	1987-05-19	Chugai Seiyaku Kabushiki Kaisha	vitamin D3 derivatives having a substituent at 2-position
US5086191A (en) *	1991-05-28	1992-02-04	Wisconsin Alumni Research Foundation	Intermediates for the synthesis of 19-nor vitamin D compounds
AU666563B2 (en) *	1992-08-07	1996-02-15	Wisconsin Alumni Research Foundation	Preparation of 19-nor-vitamin D compounds
JP2898882B2 (ja) *	1993-04-05	1999-06-02	ウイスコンシンアラムナイリサーチフオンデーシヨン	２−位に置換基を有する１９−ノル−ビタミンｄ３化合物
US5843928A (en) *	1997-03-17	1998-12-01	Wisconsin Alumni Research Foundation	2-alkylidene-19-nor-vitamin D compounds
US5945410A (en) *	1997-03-17	1999-08-31	Wisconsin Alumni Research Foundation	2-alkyl-19-nor-vitamin D compounds
ATE273709T1 (de) *	2000-09-08	2004-09-15	Wisconsin Alumni Res Found	1alpha-hydroxy-2-methylene-19-nor- homopregnacalciferol und seine therapeutische verwendungen
US6627622B2 (en) *	2002-02-18	2003-09-30	Wisconsin Alumni Research Foundation	(20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6835723B2 (en) *	2001-12-13	2004-12-28	Wisconsin Alumni Research Foundation	2-methylene-19-nor-20(S)-1α-hydroxy-bis-homo-pregnacalciferol in crystalline form
US6566352B1 (en) *	2002-02-18	2003-05-20	Wisconsin Alumni Research Foudation	1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
WO2005051323A2 (en) *	2003-11-25	2005-06-09	Wisconsin Alumni Research Foundation	Vitamin d analogs for obesity prevention and treatment
EP1831161B1 (de) *	2004-11-22	2017-07-26	Wisconsin Alumni Research Foundation	Medizinische und kosmetische verwendung von 2-methylen-19-nor-(20r)-1-alpha-hydroxy-bishomopregnacalciferol

2008
- 2008-12-24 AU AU2008345086A patent/AU2008345086B2/en not_active Ceased
- 2008-12-24 US US12/343,602 patent/US7943601B2/en not_active Expired - Fee Related
- 2008-12-24 AT AT08867299T patent/ATE552239T1/de active
- 2008-12-24 ES ES08867299T patent/ES2387714T3/es active Active
- 2008-12-24 JP JP2010540885A patent/JP2011507966A/ja active Pending
- 2008-12-24 EP EP08867299A patent/EP2240438B1/de not_active Not-in-force
- 2008-12-24 WO PCT/US2008/088276 patent/WO2009086440A1/en not_active Ceased
- 2008-12-24 MX MX2010007205A patent/MX2010007205A/es active IP Right Grant
- 2008-12-24 CA CA2710977A patent/CA2710977C/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP2240438B1 (de)	2012-04-04
US7943601B2 (en)	2011-05-17
AU2008345086B2 (en)	2014-02-13
MX2010007205A (es)	2010-09-30
WO2009086440A1 (en)	2009-07-09
EP2240438A1 (de)	2010-10-20
AU2008345086A1 (en)	2009-07-09
US20090170822A1 (en)	2009-07-02
ES2387714T3 (es)	2012-09-28
CA2710977A1 (en)	2009-07-09
CA2710977C (en)	2015-02-17
JP2011507966A (ja)	2011-03-10

Publication	Publication Date	Title
DE60215225D1 (de)	2006-11-16	Alpha-hydroxy-2-methylen-10-nor-pregnacalciferol und seine anwendungen
MX2007006263A (es)	2007-07-10	Analogos 2a-metil y 2??-metil de 19,26,27-trinor-(20s)-1a- hidroxivitamina d3 y sus usos.
ATE552239T1 (de)	2012-04-15	2-methylen-20-methyl-19,24,25,26,27-pentanor- vitamin-d-analoga
PT1315504E (pt)	2004-12-31	1-alfa-hidroxi-2-metileno-19-nor-homopregnacalciferol e suas aplicacoes terapeuticas
WO2006057899A3 (en)	2006-07-06	2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses
MX2009003241A (es)	2009-05-05	Analogos de 2-metilen-(20r,25s)-19,27-dinor-(22e)-vitamina d.
DE602005021245D1 (de)	2010-06-24	2-methylen-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and dessen verwendungen
MX2007006262A (es)	2007-07-10	2-metilen-19-nor-1a-hidroxi-17-en homopregnacalciferol y sus usos.
MX2010007264A (es)	2011-03-15	Análogos de vitamina d 2-metilen-(20s, 25r)-19, 26-dinor.
ATE552238T1 (de)	2012-04-15	2-methylen-(20s,25s)-19,27-dinor-(22e)-vitamin- - analoga
DE602005022098D1 (de)	2010-08-12	2-methylen-18,19-dinor-1alfa-hydroxy-homopregnacalciferol und dessen verwendungen
WO2010006125A3 (en)	2010-04-01	2-methylene-19,26-dinor-(20r,22e,25r)-vitamin d analogs
WO2010006169A3 (en)	2010-04-15	2-methylene-19, 26-dinor-(20s, 22e, 25r)-vitamin d analogs
WO2006057902A3 (en)	2006-07-13	2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses
WO2010006172A3 (en)	2010-04-08	2-methylene-20(21)-dehydro-19-nor-vitamin d analogs
WO2009086439A3 (en)	2009-08-27	2-methylene-(20s,25s)-19,26-dinor-vitamin d analogs
WO2010006162A3 (en)	2010-05-20	2-methylene-(20e)-20(22)-dehydro-19-nor-vitamin d analogs
WO2010006135A3 (en)	2010-04-15	2-methylene-(17z)-17(20)-dehydro-19,21-dinor-vitamin d analogs
ATE496885T1 (de)	2011-02-15	1-alpha-hydroxy-2-(3'-hydroxypropyliden)-19-nor vitamin-d-verbindungen mit einer 1,1- dimethylpropyl-seitenkette